| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, United Kingdom;
* Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, 80138 Naples, Italy; and
Department of Biology, IBILCE-UNESP, Sao José do Rio Preto, SP, Brazil
1Correspondence: Department of Biochemical Pharmacology, The William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, United Kingdom. E-mail: m.la{at}mds.qmw.ac.uk
Myocardial reperfusion injury is associated with the infiltration of blood-borne polymorphonuclear leukocytes. We have previous described the protection afforded by annexin 1 (ANXA1) in an experimental model of rat myocardial ischemia-reperfusion (IR) injury. We examined the 1) amino acid region of ANXA1 that retained the protective effect in a model of rat heart IR; 2) changes in endogenous ANXA1 in relation to the IR induced damage and after pharmacological modulation; and 3) potential involvement of the formyl peptide receptor (FPR) in the protective action displayed by ANXA1 peptides. Administration of peptide Ac2–26 at 0, 30, and 60 min postreperfusion produced a significant protection against IR injury, and this was associated with reduced myeloperoxidase activity and IL-1ß levels in the infarcted heart. Western blotting and electron microscopy analyses showed that IR heart had increased ANXA1 expression in the injured tissue, associated mainly with the infiltrated leukocytes. Finally, an antagonist to the FPR receptor selectively inhibited the protective action of peptide ANXA1 and its derived peptides against IR injury. Altogether, these data provide further insight into the protective effect of ANXA1 and its mimetics and a rationale for a clinical use for drugs developed from this line of research.—La, M., D’Amico, M., Bandiera, S., Di Filippo, C., Oliani, S. M., Gavins, F. N. E., Flower, R. J., Perretti, M. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action.
Key Words: lipocortin 1 • receptor • neutrophil • FPR • fMLP
This article has been cited by other articles:
|
|
 |
|
  D. G. Souza, C. T. Fagundes, F. A. Amaral, D. Cisalpino, L. P. Sousa, A. T. Vieira, V. Pinho, J. R. Nicoli, L. Q. Vieira, I. M. Fierro, et al. The Required Role of Endogenously Produced Lipoxin A4 and Annexin-1 for the Production of IL-10 and Inflammatory Hyporesponsiveness in Mice J. Immunol., December 15, 2007; 179(12): 8533 - 8543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Birnbaum, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat Circulation, August 29, 2006; 114(9): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. G. Hayhoe, A. M. Kamal, E. Solito, R. J. Flower, D. Cooper, and M. Perretti Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement Blood, March 1, 2006; 107(5): 2123 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bandeira-Melo, A. G. C. Bonavita, B. L. Diaz, P. M. R. e Silva, V. F. Carvalho, P. J. Jose, R. J. Flower, M. Perretti, and M. A. Martins A Novel Effect for Annexin 1-Derived Peptide Ac2-26: Reduction of Allergic Inflammation in the Rat J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1416 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Maderna, S. Yona, M. Perretti, and C. Godson Modulation of Phagocytosis of Apoptotic Neutrophils by Supernatant from Dexamethasone-Treated Macrophages and Annexin-Derived Peptide Ac2-26 J. Immunol., March 15, 2005; 174(6): 3727 - 3733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Filippo, R. Marfella, S. Cuzzocrea, E. Piegari, P. Petronella, D. Giugliano, F. Rossi, and M. D'Amico Hyperglycemia in Streptozotocin-Induced Diabetic Rat Increases Infarct Size Associated With Low Levels of Myocardial HO-1 During Ischemia/Reperfusion Diabetes, March 1, 2005; 54(3): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. O. Zanardo, M. Perretti, and J. L. Wallace Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G481 - G486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perretti and R. J. Flower Annexin 1 and the biology of the neutrophil J. Leukoc. Biol., July 1, 2004; 76(1): 25 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ernst, C. Lange, A. Wilbers, V. Goebeler, V. Gerke, and U. Rescher An Annexin 1 N-Terminal Peptide Activates Leukocytes by Triggering Different Members of the Formyl Peptide Receptor Family J. Immunol., June 15, 2004; 172(12): 7669 - 7676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. E. Gavins, S. Yona, A. M. Kamal, R. J. Flower, and M. Perretti Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms Blood, May 15, 2003; 101(10): 4140 - 4147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perretti and F. N. E. Gavins Annexin 1: An Endogenous Anti-Inflammatory Protein Physiology, April 1, 2003; 18(2): 60 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perretti, F. Ingegnoli, S. K. Wheller, M. C. Blades, E. Solito, and C. Pitzalis Annexin 1 Modulates Monocyte-Endothelial Cell Interaction In Vitro and Cell Migration In Vivo in the Human SCID Mouse Transplantation Model J. Immunol., August 15, 2002; 169(4): 2085 - 2092. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
